CP and neoplasm: However, despite its strong overexpression in PDAC, targeting of sLea in PDAC is limited by its presence in the healthy pancreas, CP and other benign pancreaticobiliary diseases, which is confirmed by the relatively low tumor:CP, tumor:pancreas and tumor:duodenum ratios found in the current study [31].